FDA Delays Cadence Drug Review: BioBuzz
SAN DIEGO, Calif. ( TheStreet) -- Another U.S. Food and Drug Administration drug review -- delayed.
This time, it's Cadence Pharmaceuticals (CADX), which said Friday that FDA is pushing back review of its intravenous acetaminophen by three months. The new approval decision date is now Feb. 12, 2010.
Last week, the FDA also delayed by three months a review of a restless leg syndrome drug by GlaxoSmithKline (GSK) and Xenoport (XNPT). The FDA has had difficulty meeting drug approval review deadline this year, in part because of staffing shortages but also because of the agency's renewed focus on drug safety.
Cadence is developing its intravenous acetaminophen for use in hospitalized patients. The drug's U.S. and Canadian marketing rights was licensed from Bristol-Myers Squibb (BMY), which already sells the drug in Europe.
Gilead Benefits From New HIV Treatment RulesEarlier this week, the European AIDS Clinical Society revised its HIV treatment guidelines, calling on doctors to start treating newly diagnosed HIV patients earlier. The new European recommendation calls for doctors to begin treating HIV patients when their CD4 counts (a key measure of immune system health) fall to 500. In the past, doctors waited until CD4 counts fell to 350 before beginning treatment. The change comes on the heels of mounting clinical evidence from large studies showing that earlier treatment benefits HIV patients. The new guidelines are a boon to drug companies that sell HIV medicines, and none will benefit more than Gilead Sciences (GILD), given its market-leading HIV drug franchise. Earlier treatment starts for newly diagnosed HIV patients will translate into more HIV patients starting therapy with Gilead's Atripla or Truvada, and for longer durations.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV